公开(公告)号：EP3290054A1

公开(公告)日：2018-03-07

申请号：EP16789510.1

申请日：2016-04-22

Applicant: Japan Science and Technology Agency

Inventor： FUKAMI Kiyoko ,  SATOW Reiko

IPC: A61K45/00 ,  A61K31/713 ,  A61K48/00 ,  A61P13/08 ,  A61P17/00 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00

CPC classification number: A61K31/713 ,  A61K45/00 ,  A61K48/00 ,  C07K14/4702 ,  C12N15/1135 ,  C12N2310/14

Abstract: The present invention provides an anti-tumor agent and a suppressor for suppressing malignant transformation such as acquisition of metastatic ability or acquisition of apoptosis resistance of a tumor cell. The present invention provides a tumor cell malignant transformation suppressor, including a substance suppressing or inhibiting Zic5 gene functions as an active ingredient to suppress or inhibit acquisition of metastatic ability or acquisition of apoptosis resistance of a tumor cell; a method of suppressing tumor cell malignant transformation of animals other than humans, including suppressing or inhibiting Zic5 gene functions to suppress or inhibit acquisition of metastatic ability or acquisition of apoptosis resistance of a tumor cell; an anti-tumor agent including a substance suppressing or inhibiting Zic5 gene functions as an active ingredient, in which the agent is used in prostate cancer therapy; and a marker for tumor cell malignancy consisting of the expression level of Zic5 gene.

Abstract translation: 本发明提供用于抑制肿瘤细胞的转移能力的获得或获得抗细胞凋亡的恶性转化的抗肿瘤剂和抑制剂。 本发明提供肿瘤细胞恶性转化抑制剂，其包括抑制或抑制Zic5基因功能的物质作为活性成分以抑制或抑制肿瘤细胞的转移能力的获得或获得细胞凋亡抗性; 抑制人以外的动物的肿瘤细胞恶性转化的方法，包括抑制或抑制Zic5基因功能以抑制或抑制获得转移能力或获得肿瘤细胞的细胞凋亡抗性; 包含抑制或抑制Zic5基因的物质作为活性成分的抗肿瘤剂，其中所述药物用于前列腺癌治疗; 和由Zic5基因表达水平组成的肿瘤细胞恶性肿瘤标志物。

公开(公告)号：EP4378481A1

公开(公告)日：2024-06-05

申请号：EP22849594.1

申请日：2022-07-28

Applicant: Japan Science and Technology Agency

Inventor： FUKAMI Kiyoko ,  SATOW Reiko

IPC: A61K45/00 ,  A61P35/00 ,  A61P43/00 ,  C12N15/113 ,  A61K31/133 ,  A61K31/365 ,  A61K31/407 ,  A61K31/58 ,  A61K31/7048 ,  A61K31/713

CPC classification number: A61K31/133 ,  A61K31/365 ,  A61K31/407 ,  A61K31/58 ,  A61K31/713 ,  A61K31/7048 ,  A61K45/00 ,  A61P35/00 ,  A61P43/00 ,  C12N15/113

Abstract: The present invention provides a pharmaceutical composition that suppresses cell proliferation and has an anti-cancer effect with respect to pancreatic cancer and bile duct cancer. The present invention relates to a pharmaceutical composition containing, as an active ingredient, a substance that reduces an intracellular content of a ZIC5 protein, where the composition is used for treatment of pancreatic cancer or bile duct cancer; the pharmaceutical composition further containing an anti-cancer agent other than the substance that reduces the intracellular content of the ZIC5 protein; and the pharmaceutical composition further containing an anti-cancer agent other than the substance that reduces the intracellular content of the ZIC5 protein.